<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644800</url>
  </required_header>
  <id_info>
    <org_study_id>A1281074</org_study_id>
    <nct_id>NCT00644800</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis</brief_title>
  <official_title>An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the
      treatment of the acute exacerbation of non-organic psychosis of any etiology, including
      schizophrenia, acute mania, delusional disorder and others.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores</measure>
    <time_frame>Days 1-3 (end of intramuscular dosing)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram at Visits 1 and 5</measure>
    <time_frame>Visits 1 (Screening) and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events at Visits 2, 3, 4, and 5</measure>
    <time_frame>Visits 2 (Day 1), 3 (Day 1, 2, 3, or 4), 4 (Day 5), and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Preference Scale (PPS) scores at Visits 3 and 5</measure>
    <time_frame>Visits 2 (Day 1), 3 (Day 1, 2, 3, or 4) and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests at Visits 1 and 5</measure>
    <time_frame>Visits 1 (Screening) and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement disorder rating scale scores (Barnes Akathisia Scale and Extrapyramidal Symptoms Rating Scale) at Visits 2, 3, 4, and 5</measure>
    <time_frame>Visits 2 (Day 1), 3 (Day 1, 2, 3, or 4), 4 (Day 5), and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PANSS excitation items scores at Visits 3, 4, and 5</measure>
    <time_frame>Visits 1 (Screening), 2 (Day 1), 3 (Day 1, 2, 3, or 4), 4 (Day 5), and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and pulse at Visits 1, 2, and 5</measure>
    <time_frame>Visits 1 (Screening), 2 (Day 1), and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity (CGI-S) scores at Visits 3, 4, and 5</measure>
    <time_frame>Visits 1 (Screening), 2 (Day 1), 3 (Day 1, 2, 3, or 4), 4 (Day 5), and 5 (Day 7)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Mania</condition>
  <condition>Delusional Disorder</condition>
  <condition>Acute Exacerbation of Psychosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients with psychosis

          -  Eligible for intramuscular treatment

          -  Miminum score of 60 on the PANSS, a score of 14 in the sum of PANSS excitation score
             and a score of at least 4 in 1 of the following items: poor control of impulses,
             tension, hostility, uncooperativeness or excitation.

        Exclusion Criteria:

          -  Treatment with antidepressants or mood stabilizers within seven days prior to the
             enrollment; for monoamine oxidase inhibitors (MAOIs) and moclobemide, this period must
             be two weeks; for fluoxetine, five weeks

          -  Resistance to conventional antipsychotic agents

          -  A history of epilepsy

          -  A diagnosis of abuse of substance within the previous 3 months according to the DSMIV
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41180-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60175-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30150-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Goncalo</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jardim Santa Monica Sn</city>
        <state>Salvador - Ba</state>
        <zip>40340-720</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281074&amp;StudyName=A%20study%20of%20the%20efficacy%20and%20safety%20of%20intramuscular%20ziprasidone%20followed%20by%20oral%20ziprasidone%20for%20the%20treatment%20of%20psychosis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Schizophrenia, Paranoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

